Oxervate (Cenegermin)

Cenegermin, the active ingredient in Oxervate, is a neurotrophic factor presented as a ophthalmic solution for topical ocular use. It treats neurotrophic keratitis in patients with damaged corneal innervation. GNH USA supplies Oxervate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty eye clinics worldwide.

GNH USA supplies Oxervate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty eye clinics worldwide.

Oxervate is a recombinant human nerve growth factor indicated for diseases affecting the ocular surface where corneal nerve deficiency occurs.

- Neurotrophic keratitis: promotes healing of the corneal epithelium and reduces persistent epithelial defects. - Severe dry eye disease associated with neurotrophic deficiency: improves corneal surface integrity. - Post‑surgical corneal nerve injury: supports regeneration of corneal nerves and accelerates recovery. - Chemical‑cautery ‑ related injury of the cornea : facilitates epithelial repair and reduces inflammation .

Cenegermin may elicit ocular and systemic reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Eye irritation : burn of the eye at administration point . - Red‑ red of the conjunct .\n- Tired  g  g  g  ewline -   t  ewline   ewline -  ewline  ewline   ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline  ewline \n-  -  -  ewline  ewline  ewline  ewline ",